These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 17607292)

  • 1. Where do our priorities lie?
    Hanauer SB
    Nat Clin Pract Gastroenterol Hepatol; 2007 Jul; 4(7):353. PubMed ID: 17607292
    [No Abstract]   [Full Text] [Related]  

  • 2. The marketplace can't give us the drug safety data we need.
    Avorn J
    MedGenMed; 2007 Feb; 9(1):29. PubMed ID: 17435636
    [No Abstract]   [Full Text] [Related]  

  • 3. New fee structure proposed by FDA might lead to more talk.
    Waters H
    Nat Med; 2011 Oct; 17(10):1159. PubMed ID: 21988966
    [No Abstract]   [Full Text] [Related]  

  • 4. Drug safety on trial.
    Nature; 2005 Mar; 434(7033):545. PubMed ID: 15800579
    [No Abstract]   [Full Text] [Related]  

  • 5. User fees for faster drug reviews. Are they helping or hurting the public health?
    Thompson L
    FDA Consum; 2000; 34(5):25-9. PubMed ID: 11590789
    [No Abstract]   [Full Text] [Related]  

  • 6. FDA joins market.
    Gershon D
    Nature; 1993 Jul; 364(6433):93. PubMed ID: 8321293
    [No Abstract]   [Full Text] [Related]  

  • 7. Food and Drug Administration.
    Horton LR
    BMJ; 2007 Jan; 334(7584):55-6. PubMed ID: 17218671
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does neurology need a faster FDA?
    Burton A
    Lancet Neurol; 2014 Aug; 13(8):760-1. PubMed ID: 25030510
    [No Abstract]   [Full Text] [Related]  

  • 9. User fees to fund faster reviews.
    Henkel J
    FDA Consum; 1993 Oct; 27(8):19-21. PubMed ID: 10129049
    [No Abstract]   [Full Text] [Related]  

  • 10. Moment of reckoning.
    Wadman M
    Nature; 2007 Apr; 446(7138):844-5. PubMed ID: 17443154
    [No Abstract]   [Full Text] [Related]  

  • 11. A proposal for radical changes in the drug-approval process.
    Wood AJ
    N Engl J Med; 2006 Aug; 355(6):618-23. PubMed ID: 16899784
    [No Abstract]   [Full Text] [Related]  

  • 12. Financial conflicts of interest are related to voting patterns at FDA Advisory Committee meetings.
    Lurie P
    MedGenMed; 2006 Oct; 8(4):22. PubMed ID: 17415305
    [No Abstract]   [Full Text] [Related]  

  • 13. US FDA feels the heat from Congressional hearings.
    Loewenberg S
    Lancet; 2008 May; 371(9624):1565-6. PubMed ID: 18476294
    [No Abstract]   [Full Text] [Related]  

  • 14. Swimming upstream: an advocate reflects on cancer research and social realities.
    Mayer M
    J Clin Oncol; 2008 Jun; 26(16):2783-6. PubMed ID: 18509190
    [No Abstract]   [Full Text] [Related]  

  • 15. Mark McClellan.
    McClellan M
    Nat Rev Drug Discov; 2009 Feb; 8(2):102. PubMed ID: 19180102
    [No Abstract]   [Full Text] [Related]  

  • 16. Assuring the benefits of modern medicine for all Americans.
    Woodcock J
    Healthplan; 2003; 44(5):23-6. PubMed ID: 14556608
    [No Abstract]   [Full Text] [Related]  

  • 17. A Food and Drug Administration primer.
    Simon LS
    Arthritis Rheum; 2006 Feb; 55(1):4-8. PubMed ID: 16463403
    [No Abstract]   [Full Text] [Related]  

  • 18. The Food and Drug Administration and its problems.
    Iglehart JK
    N Engl J Med; 1991 Jul; 325(3):217-20. PubMed ID: 2052069
    [No Abstract]   [Full Text] [Related]  

  • 19. Missing evidence.
    Hayes WS
    MLO Med Lab Obs; 2008 Oct; 40(10):68. PubMed ID: 18988559
    [No Abstract]   [Full Text] [Related]  

  • 20. Has the food and drug administration changed the drug approval process?
    Somberg JC
    Am J Ther; 2011 May; 18(3):179. PubMed ID: 21566467
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.